Coronary Stents
Types of Coronary Stents
NeoVas™ Sirolimus-eluting Bioresorbable Coronary Stent System
NeoVas™
From Recanalization to Revascularization
New Era Toward“BIORESORBABLE times
NeoVas™ Sirolimus-eluting Bioresorbable Coronary Stent System Details
Product Description
Stent Platform
Fully degradable poly(L-lactide)
Sine wave structure in space, In-phase peak-valley connection
Drug coating
Fully degradable poly(D,L-lactide)
Effectively control sirolimus release rate
Drug
Classical Sirolimus with dose of 15.3ug/mm
Inhibit the proliferation and migration of smooth muscle cells
Delivery system
Completely self-developed second-generation rapid-exchange balloon dilatation catheter
Superior pushability and crossability
NeoVas RCT Study
The study enrolled 560 subjects in 33 centers from China, Test group(NeoVas): 278 cases, Control group (Xience stent): 282 cases.
Primary endpoint: the late lumen loss in one year follow-up
Conclusion:
The clinical events rate for Neovas bioabsorbable stent is low, showed equal safety and effectiveness with Xience metal stent.
NeoVas OPC study
The study enrolled 1103 subjects in 45 centers from China, two year clinical follow-up study has been completed to date.
1-2 year follow-up result
Conclusion:
2-year follow up Clinical results for 1103 subjects demonstrate that NeoVas bioresorbable stent has equal low clinical events rate. Compared with the first generation bioresorbable stent Absorb BVS, the clinical events rate has been obviously decreased, and it indicates that NeoVas performed favorable safety and effectiveness.
The Imaging study of the NeoVas Subgroup
The subgroup analyzed the imaging and function of 166 subjects from the randomized controlled study, 83 cases for test/control group.
Conclusion：
NeoVas subgroup of 3 years clinical imaging data shows vessel vasomotor function has been restored after 3 years implantation, superior to metal stent. Blood supply keeps at favorable level. Most stent was degraded and absorbed after 3 years.
The importance of standardized PSP operations
Tips: Absorb BVS did not perform standard PSP operation and increased the safty incident
The Absorb Ⅱ/Ⅲ study shows that the safty incident of TLF and stent thrombus was significantly increased and has statistical difference with metal stent due to the failure to perform PSP operation.
Sirolimus Eluting Stent
The TLF and stent thrombus of patient using PSP and without using PSP operation in Absorb Ⅲ study
Experience: Standardized PSP operation ensures safety for Neovas Stent
The application rate of PSP operation is relatively low in Absorb Ⅱ and Absorb Ⅲ study, the TLF and stent thrombus of BVS in three years is relatively high, displays statistical difference with metal stent; the PSP operation perform rate in Absorb China study is relatively high, the TLF and stent thrombus of BVS in three years is relatively low and has no statistical difference with metal stent.
Sirolimus Stent
Comparison of stent thrombus (ST) and TLF at three years in Absorb BVS clinical study Stent thrombus (ST) and TLF at three years for NeoVas clinical study.
In Neovas clinical study, with standardized PSP operation, the TLF and ST in three years has no statistical difference. Strictly PSP operation performing is critical to significantly decrease stent adverse cardiac events.
Why PSP operation significantly decrease adverse cardiac events?
The direct reason of stent long-term adverse cardiac events (stent thrombus) is the stent malap- position during implantation. Stent malapposition will cause micro vascular dissection. For metal stent, stable new vessel wall will be formed after revascularization and endothelialization supported by metal stent. For bioresorbable stent, this vessel wall is unstable due to the stent degradation. Stent even breaks at thin endothelializaton tissue area and leads to the direct connection between blood and micro vascular dissection, this will cause stent thrombus rate increased higher compared with metal stent.
The objects of the regulated PSP operation is to ensure the stent apposition and exclude the vascular dissection.
Sirolimus-eluting Bioresorbable Coronary Stent System.
First brand launched in China.
Nano+™ Polymer-free Sirolimus-eluting Coronary Stent System
Nothing Beats Free
GuReater<sup>®</sup>CoCr Stent Sirolimus-eluting Coronary Stent System
GuReater®CoCr Stent Sirolimus-eluting Coronary Stent System
CoCr Stent Sirolimus-eluting Coronary Stent System
Partner<sup>®</sup>Sirolimus-eluting Coronary Stent System
Partner®Sirolimus-eluting Coronary Stent System
Sirolimus-eluting Coronary Stent System.
Classical stainless steel stent.
H-Stent™ Coronary Stent System
Coronary Stent System
As one of medical equipment manufacturers in china, we can offer sorts of medical devices chinafor sale with reasonable prices, if you are interested, please leave us a message.
Send product request
Other supplier products
 |
Norfloxacin | Medicine Norflox Item/Code CAS No. Molecular Structure Therapeutic Area Certification/Stage API 70458-96... |
 |
Clopidogrel Bisulfate | Clopidogrel Hydrogen Sulfate Item/Code CAS No. Molecular Structure Therapeutic Area Certification/Stage API ... |
|
|
Coronary Stents | Types of Coronary Stents NeoVas™ Sirolimus-eluting Bioresorbable Coronary Stent System NeoVas™ From Recanalization to Revascularizat... |
 |
3-Aminopyrazine -2- carboxylic acid | 3-Aminopyrazine -2- carboxylic acid Item/Code CAS No. Molecular Structure Therapeutic Area Certification/Stage ... |
 |
LEN503 Nebulizer | Cute pet caring Small atomized particles Adjustable atomizing cup High-quality compressor LEN503 Nebulizer Details Cute pet caring ... |
